Analyst consensus rating
Eikon Therapeutics Analyst Rating: Buy
EIKN is rated Buy by 5 analysts with a $24.60 target. As of 2026-08-25.
Direct answer
Eikon Therapeutics's consensus rating is Buy.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $24.60.
Forecast evidence checked August 25, 2026.
Get free Eikon Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $12.65
- Average price target
- $24.60
- High price target
- $32.00
- Low price target
- $4.00
- Low target gap
- -68.4%
- Target upside
- +94.5%
- High target gap
- +153.1%
- Target range width
- 221.4%
- Consensus rating
- Buy
- Analysts
- 5
- Evidence date
- August 25, 2026
- Valid through
- September 1, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Eikon Therapeutics?
Eikon Therapeutics has a verified Buy consensus. The same dataset has an average price target of $24.60.
How far are Eikon Therapeutics's low and high targets from the recorded price?
The low target implies -68.4%, while the high target implies +153.1%.
How many analysts are included in Eikon Therapeutics's consensus?
The verified consensus includes 5 analysts.
How is Eikon Therapeutics's target upside or downside calculated?
The average target of $24.60 is divided by the recorded price of $12.65, then one is subtracted to produce +94.5%. This does not guarantee a future return.
When was Eikon Therapeutics's analyst forecast verified?
The data was verified on 2026-08-25. The dataset is valid through 2026-09-01.